← Home / MOONLAKE IMMUNOTHERAPEUTICS (MLTX)
Stock Analysis
MOONLAKE IMMUNOTHERAPEUTICS (MLTX)
MLTX
MLTX · Market data
19.19 +1.11%
52W Range Position
23%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-06-18 13:38 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 21.64. Holding above 19.01 keeps the current thesis intact.
⚖️
Fundamentals
Insufficient / Insufficient
Price Structure
Constructive
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
Hold Above
Structure remains valid above support.
19.01
Break Above
Confirmation improves above resistance.
21.64
🎯
Next Objective
Pattern-derived target if setup continues.
23.44
×
Thesis Break
Scenario weakens below invalidation.
Below 19.01
What's Driving MLTX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 21.64 for confirmation and 19.01 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 17.91 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Technical Setup Active
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Pattern
Triangle Compression / SYM / UP
State
Active
Trigger
18.20
Target
23.44
Risk / Invalid
15.40
Breakout Watch
Downtrend line not broken yet · score 0
Compression
52%
How to read this setup
From a roadmap perspective, the setup is boxed by support near 17.91 and resistance around 21.64. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
MLTX · WOI overlay chart
Open Full Workspace
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
Revenue Growth
Insufficient
Profitability
Insufficient
Cash Flow
Mixed
Balance Sheet
Manageable
📈 Net Income
-69.71M
≈ Insufficient
🧮 EPS (Basic)
-0.98
≈ Insufficient
MOONLAKE IMMUNOTHERAPEUTICS
Note: This is an algorithmic technical snapshot, not financial advice.